Posttransplant malignancies in liver transplant recipients

Experimental and Clinical Transplantation

Volumn 12, Issue SUPPL. 1, 2014, Pages 162-165

  Akdur, Aydincan ^a   Kirnap, Mahir ^a   Yildirim, Sedat ^a   Altundaǧ, Özden ^a   Moray, Gökhan ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Liver failure; Posttransplant lymphoproliferative disorder (PTLD); Thyroid papillary carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; EARLY DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; GRAFT RECIPIENT; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVARY CARCINOMA; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; ADULT; CHILD; FEMALE; INFANT; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; PRESCHOOL CHILD; RISK FACTOR; TIME; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

ADULT; CHILD; CHILD, PRESCHOOL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84897380937     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.25Liver.P42     Document Type: Article

References (11)

1. Herrero JI. Screening of de novo tumors after liver transplantation. J Gastroenterol Hepatol. 2012;27(6):1011-1016.
2. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15(suppl 2):S90-S94.
3. Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008;14(10):1428-1436.
4. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol. 2006;44(1):27-32.
5. Herrero JI, España A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11(9):1100-1106.
6. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation. 1997;64(10):1438-1442.
7. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80(7):883-889.
8. Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767-1769.
9. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34(1):84-91.
10. Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term followup. Clin Transplant. 2006;20(5):617-623.
11. Schrem H, Kurok M, Kaltenborn A, et al. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl. 2013 Sep 14. doi: 10.1002/lt.23722. [Epub ahead of print]